CSIMarket


Tengjun Biotechnology Corp   (CHGH)
Other Ticker:  
 


 

Tengjun Biotechnology Corp

CHGH's Financial Statements and Analysis



Tengjun Biotechnology Corp reported break-even for the second quarter of 2023 compare to earnings per share of $0.06 recorded in the same quarter a year ago an improvement compare to $0.00 realized in previous quarter.


second quarter of 2023
Earnings Per Share Revenues
$ 0 $  0 Mill
$-0.06     $-51M    



Tengjun Biotechnology 's Revenue fell by 0 % in second quarter of 2023 (Jun 30 2023) year on year, to $0 million and declined by sequentially.


Tengjun Biotechnology is Expected to report next financial results on April 16, 2024.

More on CHGH's Income Statement



Tengjun Biotechnology 's in thesecond quarter of 2023 recorded net loss of $-0.467 million, compare to net income of $4.134 million achieved in II. Quarter a year ago.

Sequentially company realized a net loss, compared to net income of $0.391 million in the previous quarter.

More on CHGH's Growth

Tengjun Biotechnology Inventories
Inventories grew by 85.97 % to $2 million from II. Quarter a year ago, sequentially inventories rose by 120.59 %. CHGH's Cash flow In the second quarter of 2023 company's net cash flow was $13 million


Tengjun Biotechnology Corp does not pay out common stock dividend.

In trailing twelve-month period Tengjun Biotechnology Corp earned $ 0.22 cash per share, on a free-cash flow basis 361.54 % of net earning per share.

Book value fell by -4.30 % sequentially to $0.15 per share.
Tangible Book value fell to $ 0.15 per share from $ 0.16.

Company issued 1.15 million shares or 1.16 % in Jun 30 2023.
Interest Coverage Ratio was 274.15.

More on CHGH's Dividends

 Market Capitalization (Millions) -
 Shares Outstanding (Millions) 100
 Total Debt (Millions $) -
 Revenue (TTM) (Millions $) -
 Net Income (TTM) (Millions $) 7
 Cash Flow (TTM) (Millions $) 18
 Capital Exp. (TTM) (Millions $) 0
 Dividend TTM ($) 0 $
 Dividend Yield TTM (%) -
 Employees (TTM) $ -




Tengjun Biotechnology Corp does not pay out common stock dividend.

In trailing twelve-month period Tengjun Biotechnology Corp had $ 0.22 cash flow per share, on a free-cash flow basis 361.54 % of net earning per share.

Book value fell by -4.30 % sequentially to $0.15 per share.
Tangible Book value fell to $ 0.15 per share from $ 0.16.

Company issued 1.15 million shares or 1.16 % in Jun 30 2023.
Interest Coverage Ratio was 274.15.

More on CHGH's Balance Sheets

 Market Capitalization (Millions) -
 Shares Outstanding (Millions) 100
 Total Debt (Millions $) -
 Revenue (TTM) (Millions $) -
 Net Income (TTM) (Millions $) 7
 Cash Flow (TTM) (Millions $) 18
 Capital Exp. (TTM) (Millions $) 0
 Dividend TTM ($) 0 $
 Dividend Yield TTM (%) -
 Employees (TTM) $ -
   


  News about Tengjun Biotechnology Corp Earnings

Tengjun Biotechnology Corp delivers staggering revenue results, surpassing last year's figures in the second quarter of 2023 earnings season



As the second quarter of 2023 earnings season comes to a close, investors have received a mixed bag of results from CHGH and Tengjun Biotechnology Corp. While both companies have experienced significant changes compared to the same reporting season a year ago, the overall performance raises questions about their future direction.
CHGH, while achieving balanced books with $0.00 per share, has seen a decline from $0.06 per share in the previous year. Revenue remained stagnant at $0.00 million, down from $51.29 million in the same reporting season a year earlier and $8.52 million sequentially. This lack of revenue growth indicates the need for CHGH to explore strategies that can reignite growth an...

Tengjun Biotechnology Corp Demonstrates Mixed Financial Results, Reports Revenue Surge of 98.796% in Q1 of 2023 Earnings Season

Tengjun Biotechnology Corp, a company engaged in the research, development, and production of bioactive peptides, showed mixed financial results for the fiscal span closing March 31, 2023. The company reported earnings of $0.00 per share, down from $65,309,169.00 a year prior, and from $0.02 per share from the previous reporting season. However, the company's revenue rose by 98.796% to $8.52 million from $4.28 million in the same reporting season a year before. Sequentially, revenue tumbled by -85.353% from $58.14 million.
Although the company reported a decline in net profits to $0.391 million, down by -31.78% from 0 in the corresponding period a year before, the company's operating earnings increased b...


Date modified: 2023-08-20T13:10:01+00:00





Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com